Expertise in
6
conditions

Olga V. Aleinikova

Hematology And Immunology, MI, BY 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Hematology And Immunology, MI, BY 

Overview

Olga Aleinikova practices practicing medicine in Hematology And Immunology, Belarus.

Ms. Aleinikova is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Nijmegen Breakage Syndrome, Acute Lymphoblastic Leukemia (ALL), Leukocyte Adhesion Deficiency Type 1, Atelosteogenesis Type 1, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Hematology And Immunology, MI, Belarus
Other Locations
Minsk, HM, Belarus
Borovlyany, MI, Belarus

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
Pilot Study of Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Leukemia
Pilot Study of Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Leukemia
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Drug, Biological
Study Drugs: Expanded Haploidentical Natural Killer cells, IL-2
Study Phase: Phase 1
View 2 Less Clinical Trial

44 Total Publications

Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Journal: Cancer medicine
Published: November 17, 2023

Frequently Asked Questions about Olga V. Aleinikova

Is Olga V. Aleinikova a top-rated expert for Nijmegen Breakage Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Olga V. Aleinikova is classified as an Distinguished expert for Nijmegen Breakage Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olga V. Aleinikova participate in research or clinical trials?

Yes. Olga V. Aleinikova has published 44 articles and abstracts on conditions like Nijmegen Breakage Syndrome. You can view a list of Olga V. Aleinikova's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aleinikova's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile